Biotech index hits 5th straight record close, surging 2.2%

The Nasdaq Biotechnology Index closed at a record high for the fifth consecutive session on Friday, rising 2.2% as a broader tech selloff deepened.

The Nasdaq Biotechnology Index rose 2.2% to a fifth straight record close on Friday, extending a rally that has added more than 11% over the streak as investors rotated into defensive healthcare stocks.

"The biotech sector is benefiting from a rotation out of high-multiple tech names into areas with more reasonable valuations and tangible pipeline catalysts," said Sam Goldstein, healthcare analyst at Edgen. "The index's five-day winning streak reflects both defensive flows and company-specific catalysts."

Pyxis Oncology led gainers with a 24.2% surge, followed by Humacyte, ATAI Beckley, Moderna, Immunitybio Inc., GH Research and Abcellera Biologics, which rose between 18.1% and 10.8%. Compass Pathways added 9.2%. On the downside, Omeros Corp. fell 19.2%, Mesoblast dropped 9%, Ardelyx lost 8.5% and Kymera declined 7.3%. Trading volume across the index was elevated as fund managers adjusted positions ahead of the quarter-end rebalancing.

The biotech rally stands in stark contrast to the broader market, where the S&P 500 fell 2% for the week and the Nasdaq Composite lost 4.6% — its second-worst weekly decline in the past year. Healthcare was the best-performing S&P 500 sector for the week, climbing more than 7%, as investors rotated out of technology and communications stocks, which fell 5.2% and 5.5%, respectively.

Rotation Fuels Biotech's Outperformance

The move into biotech reflects a broader shift toward defensive positioning that played out across equity markets this week. Real estate and utilities each gained about 3.5%, while consumer staples rose 1.6%. The 10-year Treasury yield ticked down to 4.38%, further supporting interest-rate-sensitive healthcare stocks. The Russell 2000 index of smaller companies, which includes many biotech names, rose 0.1% on Friday and gained 1% for the week.

For investors, the sustained rally raises questions about whether biotech can maintain momentum. The index has risen for five consecutive sessions without a pullback, suggesting some names may be approaching overbought territory. However, with the broader market facing headwinds from elevated interest rates and uncertainty around tech earnings, biotech's defensive characteristics and pipeline-driven upside could continue attracting inflows. The SPDR S&P Biotech ETF (XBI) has benefited from the rotation, though the sector's long-term performance will depend on clinical data readouts and FDA decisions in the coming months. Moderna, one of the index's largest components by market value, has been a key driver of the rally as investors weigh its pipeline beyond Covid-19 vaccines.

This article is for informational purposes only and does not constitute investment advice.